Navigation Links
EntreMed Raises $20 Million to Support Clinical Development Program
Date:9/17/2007

Secured Financing Led by GE Healthcare Financial Services

ROCKVILLE, Md., Sept. 17 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has completed a $20 million secured loan agreement with a syndicate of lenders led by GE Healthcare Financial Services, and participated by Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc., and Oxford Finance Corporation. The full amount of the $20 million loan, less fees, was funded at closing.

James S. Burns, EntreMed President and Chief Executive Officer, commented on the financing, "This transaction provides EntreMed with a non-dilutive financing vehicle that strengthens our cash position and will fund anticipated clinical development expenses into 2009. The loan collateral includes EntreMed's interest in royalty revenues on sales of Celgene's Thalomid(R). We have been funded by three leading commercial finance organizations that specialize in life science companies, and I am grateful for their confidence in EntreMed."

Mr. Burns further commented, "Proceeds from this transaction will be used primarily to support development costs for our ongoing clinical studies with Panzem(R) NCD, MKC-1, and ENMD-1198, and to fund IND-directed activities for Panzem(R) in rheumatoid arthritis and our Aurora-angiogenesis inhibitor in oncology."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
9. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
10. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Three Independent Clinical Trials Initiated with Teplizumab Manufactured at ... ... that its Protege trial is actively enrolling adults and children ages,8 to ... evaluate the safety and efficacy of three teplizumab dosing,regimens administered at the ...
... versus 26.2 for ... Vidaza compared to ... conventional ... modifier to show survival benefit in cancer Stratified log-rank p-value = 0.0001, Hazard ...
Cached Medicine Technology:MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 2MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 3MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 2Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 3Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 5Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 6Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 7Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 8
(Date:7/9/2014)... common type of lung cancer, researchers have uncovered mutations ... forming tumors. The new knowledge may expand treatments for ... already are available or are in clinical trials. , ... The Cancer Genome Atlas (TCGA), including researchers at Washington ... School and other institutions, studied tumors from 230 patients ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2
... to debate on the supplement but doesn,t settle it, one ... Glucosamine sulfate, a popular dietary supplement purported to ease the ... people with arthritis in their hips. , That,s the conclusion ... a placebo for the treatment of mild to moderate hip ...
... named the,fastest growing PR agency in the U.S., announced ... Symposium," showcasing exclusive consumer,brands from 5W,s Health & Beauty ... April 22nd from 10 a.m. to 2 p.m. at ... Hearst building and near the Time,Warner Center., This ...
... to Industry Best-Practices, MINNEAPOLIS, Feb. ... established national healthcare consulting practice, has ... which a PBM or Health,Plan can ... core organizational quality, customer service, communications ...
... Radiology Group (FRG),and the Brownsville Tri-County Hospital have ... Brownsville,s exclusive provider of,diagnostic imaging services., "The ... work,with," stated Richard W. Hritz, CEO of the ... involvement in working to bring this,hospital back online, ...
... 18 In rural Milledgeville,Georgia, 62 year old insulin-dependent ... 10,000+ mile perimeter walk of the United,States raising awareness ... "I,ve hit milestones in San Diego, Seattle, Chicago, Boston, ... of diabetes, only,fewer resources to manage it. We can ...
... Feb. 18 Be aware, be,prepared and take ... State University trauma expert on,preventing tragedies like the ... Briana Nelson Goff, associate dean of K-State,s College ... and human services,leads the Trauma Research, Education and ...
Cached Medicine News:Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 2Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 3Health News:5W Public Relations Hosts Exclusive Beauty & Wellness Industry Event 2Health News:Halleland Health Consulting Assists PBMs in Achieving URAC Accreditation for Pharmacy Benefit Management 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 3Health News:Mr. Diabetes(R) Hits 9,000 Mile Mark of 10,000+ Mile Walk to Raise Awareness About Diabetes 2Health News:K-State Trauma Researcher Says Being Prepared, Taking Action Are Vital in Preventing Tragedies Like the One at NIU 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: